表纸
市场调查报告书

数位形势:发炎性肠道疾病 (IBD)

Digital Landscape: Inflammatory Bowel Disease

出版商 GlobalData 商品编码 696560
出版日期 内容资讯 英文 159 Pages
订单完成后即时交付
价格
Back to Top
数位形势:发炎性肠道疾病 (IBD) Digital Landscape: Inflammatory Bowel Disease
出版日期: 2018年09月06日内容资讯: 英文 159 Pages
简介

本报告提供支撑从轻度到中度及从中度到重度的克隆氏症 (CD) 和溃疡性大肠炎 (UC)的病理修饰疗法 (DMT) 的,美国和EUCAN (加拿大和EU5个国家)的制药企业的数位活动调查分析,患者/HCP (医疗机关) 的数位活动相关的系统性资讯。

摘要整理

最近的趋势

形势与分析

  • 美国:患者的活动
  • 美国:HCP的活动
  • EUCAN:患者的活动
  • EUCAN:HCP的活动

附录、调查手法

目录
Product Code: GDHC043SP

"Digital Landscape: Inflammatory Bowel Disease (IBD)", analyzes digital activities undertaken by pharma industry in support of disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn's disease and ulcerative colitis (UC).

The report includes digital activities directed towards patients and/or HCPs.

The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain).

Key Highlights:

  • US Patients: AbbVie offers the strongest support for IBD patients in the US, particularly branded, unbranded and mobile app. Janssen was the most active competitor in the branded and social media spaces in 2017. Branded activity also seen from pipeline and biosimilar competitors. No IBD-specific mobile apps detected from pharma. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app.
  • US HCPs: Good support available for US HCPs in the IBD branded space, with Stelara and Humira activity detected from Janssen and AbbVie in 2017, respectively. Unbranded and mobile app landscapes are sparse. Opportunities may exist to develop or sponsor content with trusted non-pharma organizations; social media activity restricted to corporate accounts.
  • EUCAN Patients: Good brand support for patients in Germany, the UK, and Canada, with IBD-specific activity detected from Takeda and Janssen in 2017. No multi-country unbranded from biologics manufacturers with Ferring providing the only example. Unbranded support is strongest in Germany overall, with new sites launched by Janssen and Pfizer in 2017. Social media support is weak overall; EUCAN IBD patients have access to good mobile app offerings, however none detected in Italy.
  • EUCAN HCPs: The EUCAN HCP landscape is underdeveloped. Most branded activity limited to Germany or the UK with all new activity seen in the UK in 2017. The unbranded and mobile app landscapes are particularly sparse, and partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.

Companies Mentioned: AbbVie, Janssen, Takeda, UCB, MSD / Merck, Pfizer, Roche / Genentech, Gilead, Allergan, Ferring, Shire, Salix, Dr. Falk Pharma, TillottsPharma, Warner Chilcott.

Scope:

  • This report analyzes digital activities undertaken by pharma in support of therapies for disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn's disease and ulcerative colitis (UC).
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January - December 2017.

Reasons to buy:

  • Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital IBD space, and can assist our pharma clients derive value in a number of ways -
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in IBD
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in IBD and beyond, and learn about key patient and physician online activities in IBD.

Table of Contents

  • Executive Summary

Recent Developments

  • Landscape & Analysis
  • US: Patient-directed Activities
  • US HCP-directed Activities
  • EUCAN Patient-directed Activities
  • EUCAN HCP-directed Activities
  • Methodology
Back to Top